A retrospective study to investigate the recurrence rate of exudative age-related macular degeneration (wet AMD) in patients treatment with anti–vascular endothelial growth factor (anti-VEGF) bevacizumab therapy
Latest Information Update: 20 May 2021
At a glance
- Drugs Bevacizumab (Primary)
- Indications Wet age-related macular degeneration
- Focus Therapeutic Use
- 20 May 2021 New trial record